- Market Capitalization, $K 55,801
- Shares Outstanding, K 16,081
- Annual Sales, $ 28,800 K
- Annual Income, $ 9,390 K
- 60-Month Beta 0.87
- Price/Sales 2.05
- Price/Cash Flow 6.32
- Price/Book 3.98
|Period||Period Low||Period High||Performance|
| || |
-0.91 (-20.78%)since 03/03/20
| || |
-2.75 (-44.21%)since 01/03/20
| || |
-9.63 (-73.51%)since 04/03/19
AVEO Oncology (NASDAQ: AVEO) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tivozanib, the Company's vascular endothelial growth factor...
AVEO ceases the phase II CyFi-2 study on ficlatuzumab plus high-dose cytarabine for treating patients with relapsed/refractory acute myeloid leukemia to combat the COVID-19 outbreak.
AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced the discontinuation of their CyFi-2 study, a randomized Phase 2 clinical study evaluating ficlatuzumab, AVEO's potent hepatocyte growth factor...
Even though AVEO Pharmaceuticals (AVEO) reports narrower-than-estimated loss in the fourth quarter, its revenues miss the mark.
AVEO (AVEO) delivered earnings and revenue surprises of 51.72% and -63.62%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass. (AP) _ AVEO Pharmaceuticals Inc. (AVEO) on Monday reported a fourth-quarter loss of $4.5 million, after reporting a profit in the same period a year earlier.
AVEO Oncology (NASDAQ: AVEO) today reported financial results for the full year ended December 31, 2019 and provided a business update.
AVEO (AVEO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
During CannTrust's (CTST) fourth-quarter earnings call, investor focus will be on the updates pertaining to the company's default status reports and completion of its remediation activities.
On Axsome's (AXSM) fourth-quarter earnings call, investors will look for its progress with the CNS pipeline candidates and the regulatory updates on the same.